Current Report Filing (8-k)
May 13 2019 - 6:02AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
May 10, 2019
(Date
of Reportdate of earliest event reported)
Aptose
Biosciences Inc.
(Exact Name of Registrant as Specified in Its Charter)
|
|
|
|
|
Canada
(State or Other Jurisdiction of
Incorporation or Organization)
|
|
001-32001
(Commission File Number)
|
|
98-1136802
(I.R.S. Employer
Identification No.)
|
|
|
|
251 Consumers Road, Suite 1105
Toronto, Ontario M2J 4R3 Canada
(Address of Principal Executive Offices)
|
|
|
|
M2J 4R3
(Zip Code)
|
(647)
479-9828
(Registrants Telephone Number, Including Area Code)
Check the appropriate box below if the
Form 8-K
filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to
Rule 14a-12
under the Exchange
Act (17 CFR
240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to
Rule 14d-2(b)
under the Exchange Act (17 CFR
240.14d-2(b))
|
☐
|
Pre-commencement
communications pursuant to
Rule 13e-4(c)
under the Exchange Act (17 CFR
240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule
12b-2
of the Securities Exchange Act of 1934
(§240.12b-2
of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
Title of each class
|
|
Trading Symbol(s)
|
|
Name of each exchange on
which registered
|
Common Shares, no par value
|
|
APTO
|
|
The Nasdaq Stock Market
|
Explanatory Note
On May 7, 2019, Aptose Biosciences, Inc. entered into a common shares purchase agreement (the Purchase Agreement) with Aspire
Capital Fund, LLC (Aspire), pursuant to which Aspire committed to purchase up to an aggregate of $20,000,000 of our common shares at our request from time to time for up to 30 months. On May 10, 2019, we filed with the SEC a
prospectus supplement to our effective shelf Registration Statement on Form
S-3
(File
333-230218)
registering all of the common shares that may be offered to Aspire from
time to time. We are filing the opinion of our Canadian counsel, McCarthy Tetrault LLP, relating to the legality of the common shares offered and sold pursuant to the Purchase Agreement, as Exhibit 5.1 hereto.
Item 7.01 Regulation FD Disclosure.
On
May 10, 2019, we issued a press release announcing the commencement of previously announced $20.0 million common share purchase agreement with Aspire. A copy of the press release is attached as Exhibit 99.1 and incorporated herein by reference.
In accordance with General Instruction B.2 of Form 8-K, the information in the press release attached as Exhibit 99.1 hereto shall not be
deemed to be filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), nor shall such information be deemed incorporated by reference in any filing under the Securities Act of
1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Item 9.01. Financial
Statements and Exhibits.
(d) Exhibits.
1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed
on its behalf by the undersigned hereunto duly authorized.
Date: May 10, 2019
|
|
|
APTOSE BIOSCIENCES INC.
|
|
|
By:
|
|
/s/ Gregory K. Chow
|
Name:
|
|
Gregory K. Chow
|
Title:
|
|
Senior Vice President & Chief Financial Officer
|
2
Aptose Biosciences (NASDAQ:APTO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aptose Biosciences (NASDAQ:APTO)
Historical Stock Chart
From Apr 2023 to Apr 2024